Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207648 · ClinicalTrials.gov registry record
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
A clinical trial, sponsored by EMD Serono.
- Completed
- Registry status
- 307
- Enrollment target
NCT01207648 is a clinical trial that has completed, run by EMD Serono. The registered enrollment target is 307 participants.
The verdict
NCT01207648 has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- 307 participants
- Enrollment target
Study Summary
The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon \[IFN\]-beta-1a) in children and adolescents, using information already recorded in medical records. The study duration is 13 July 2010 (first data collected) to 13 July 2011 (last data collected). In this study, Data of the subjects evaluated between 1997 and 2009 was observed.
Interventions
- DRUG Rebif®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01207648
The ClinicalTrials.gov registry entry for NCT01207648 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rebif® is the first listed.
NCT01207648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01207648 about?
NCT01207648 is a clinical study titled "Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)". The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon \[IFN\]-beta-1a) in children and adolescents, using information already recorded in medical records. The study duration is 13 July 2010 (first data collected) to 13 July...
What is the current status of trial NCT01207648?
This trial is currently completed. The enrollment target is 307 participants. The study started on 2010-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01207648?
The interventions under investigation include: Rebif® (DRUG).
Who is sponsoring clinical trial NCT01207648?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.